SAN DIEGO, May 16, 2018 /PRNewswire/ -- Epic Sciences announced today that new data will be presented on studies
"Together the studies are establishing the clinical utility of the Epic platform to enable predictive medicine," said Ryan Dittamore, chief of medical innovation at Epic Sciences. "The breadth and impact of the data presented demonstrates the value of our product portfolio for the use in therapy selection, including deep insights into tumor heterogeneity and context of therapeutic resistance which isn't seen through tissue or other liquid biopsy techniques."
In partnership with the Duke Cancer Institute, a new study will be presented in an oral abstract titled "The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E)," which investigated the validation of Epic's nuclear-localized AR-V7 test, now, on market as the Oncotype DX® AR-V7 Nucleus Detect™, in the context of patient outcomes.
Furthermore, new genomic instability biomarker will be investigated in the context of PARPi therapy outcomes in a poster discussion titled, "Phenotypic and genomic characterization of CTCs as a biomarker for prediction of veliparib therapy benefit in mCRPC."
Following is a list of abstracts:
Visit Epic Sciences for a complete list of abstracts and for more information about Epic during ASCO.
Genitourinary Prostate Cancer:
Breast Cancer – Metastatic:
About Epic Sciences
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic Sciences' mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient's journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells. Epic Sciences No Cell Left Behind® technology helps match patients to therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Epic Sciences has partnered with Genomic Health to commercialize the Oncotype DX® AR-V7 Nucleus DetectTM test, which helps with therapeutic decisions between taxane chemotherapy or androgen-directed therapeutics in metastatic castrate-resistant prostate cancer. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic Sciences' goal is to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices. Epic Sciences is headquartered in San Diego.
Further information is available on the Company's website, www.epicsciences.com. Stay in touch on Linkedin, on Twitter @EpicSciences or on Facebook.com/EpicSciences.
View original content:http://www.prnewswire.com/news-releases/epic-sciences-and-its-collaborators-to-present-new-data-at-asco-2018-300649718.html
SOURCE Epic Sciences, Inc.
Subscribe to our Free Newsletters!
Osteolysis refers to breaking down of bone tissue. Bone loss occurs due to resorption of bone by ...
Patisiran injection, recently approved by FDA to treat polyneuropathy, a disease that causes ...
Dysgraphia or disorder of written expression is a childhood learning disorder marked by poor ...View All